Signatera™ for Anal Cancer

Knowing earlier can make a difference.

After chemoradiation for anal cancer, many patients may question if the treatment was effective. Signatera™ is a personalized blood test that looks for tumor DNA (ctDNA) in your blood which may be an early sign that cancer may still be present.

Speak with an expert

SGN_WB_PT_Anal_20260326_NAT-8023865_TextImage-01

Why ctDNA testing with Signatera™ can help inform therapy decisions

Scans and exams are important, but very small amounts of cancer can be hard to detect. ctDNA testing looks for tiny fragments of tumor DNA in the blood. It is built from your tumor, so it is designed to track your cancer’s unique “fingerprint” over time.

Questions Signatera™ may help support in anal cancer

Your doctor may use Signatera™ as another tool, along with scans and exams to help answer questions like:

After chemoradiation: Is the treatment working?
During follow-up: Are there early signs that the cancer may be coming back?
If a result changes: Should more testing or closer follow-up be considered?
Published research in anal squamous cell carcinoma showed that Signatera™ results during treatment and surveillance were associated with differences in outcomes. If ctDNA is detected after treatment or during follow-up, your doctor may want to monitor you more closely with scans and other tests since patients who are ctDNA positive are at a higher risk of recurrence.

SGN_WB_PT_Anal_20260326_NAT-8023865_TextImage-02

Ordering Signatera™

SGN_WB_PT_HCC_Images_20260126_NAT-8023483_Cards-01

Built from your tumor

Signatera™ is a personalized ctDNA blood test. A one-time tumor sample is used to create your personalized test.

SGN_WB_PT_MucleInv_Bladder_20260303_NAT-8023735_CardGrid-02

Designed to track tumor DNA over time

After your test is created, your doctor may order Signatera™ as part of follow-up blood draws over time. Results are reviewed together with scans, exams, and other parts of your care plan.

SGN_WB_PT_Lung_Images_20260123_NAT-8023481_3Cards-03

Monitoring during follow-up

Using your tumor tissue, Signatera™ is designed to look for your cancer’s specific “fingerprint” in the blood.

Is Signatera™ for anal cancer right for you?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Romesser, P.B. et al. Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69984-y